Fireside Chat, Interview
Regeneron CEO Dr. Leonard Schleifer on Science-Driven Success
- Regeneron plans to expand its pipeline to nearly 50 drug candidates across allergic diseases, obesity, multiple myeloma, and lung cancer while aiming to grow its workforce to 15,000 employees by 2025.
- The company currently offers approximately 12 approved or authorized drugs globally and intends to increase its genomic sequencing volume from 3 million to 50 million people to generate a dataset sufficient for AI-driven medical pattern recognition.
- Regeneron anticipates the eventual capability to conduct experiments using data rather than physical trials and expects to invest in AI to improve the efficiency of drafting protocols and creating archetype files for multi-page BLAs, though full AI integration for drug discovery remains distant.
- Leaders project that AI could eventually assist in tailoring medical practices based on individual genetic data, such as recommending specific screenings, but acknowledge that AI will not immediately provide a cure for Alzheimer's disease.
- The firm expresses an intention to potentially arrest neurodegenerative diseases like Alzheimer's and Parkinson's by treating patients before symptom onset in the "not too distant future," while noting that this outcome is not certain for all conditions, such as ALS.
- Regeneron intends to organize massive datasets, including 90 million medical records acquired through Truveta, to create a comprehensive "Bloomberg Terminal of Health," although the specific methodology for achieving this remains unconfirmed.
- The company prioritizes a physician-led culture focused on patient benefit over quarterly earnings guidance, committing to avoiding ethical "gray" areas and making decisions intended to "do the right thing."